Annual report pursuant to Section 13 and 15(d)

Statements of Cash Flows

v3.20.1
Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Operating activities      
Net loss $ (55,744) $ (35,317) $ (19,688)
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:      
Depreciation and amortization 4,777 4,539 4,990
Amortization of premium (accretion of discount) on marketable securities (1,457) (527) 106
Stock-based compensation 10,312 2,872 1,391
Revaluation of redeemable convertible preferred stock warrant liability   (973) 186
Recognition of income on derivative liability (115) (854)  
Loss on disposal of property and equipment 275    
Other 193 337 103
Impairment of long-lived assets     2,742
Changes in operating assets and liabilities:      
Accounts receivable (3,809) (865) (1,047)
Prepaid expenses and other assets (1,441) (2,220) (354)
Accounts payable 2,253 209 (473)
Accrued compensation (200) 2,578 451
Other liabilities 186 551  
Deferred rent (67) 48 86
Deferred revenue (20,186) 42,305 (25,566)
Net cash (used in) provided by operating activities (65,023) 12,683 (37,073)
Investing activities      
Purchases of marketable securities (196,226) (81,463) (14,220)
Maturities of marketable securities 128,576 2,750 34,850
Sales of marketable securities 20,000   15,208
Purchases of equipment and leasehold improvements (3,481) (1,557) (3,316)
Proceeds from exercise of options for SutroVax shares   80 80
Net cash (used in) provided by investing activities (51,131) (80,190) 32,602
Financing activities      
Payments of debt (5,000)    
Proceeds from issuance of debt     15,000
Payment of debt issuance fees     (170)
Proceed from issuance of common stock options and warrants 180 134 95
Taxes paid related to net shares settlement of restricted stock units (297)    
Proceeds from employee stock purchase plan 1,260    
Proceeds (interest) from payment of note receivable by stockholder   208 (1)
Proceeds from issuances of redeemable convertible preferred stock, net of issuance costs   84,739  
Proceeds from issuances of common stock upon initial public offering, net of issuance costs   74,436  
Payment of offering costs (327)   (286)
Proceeds from issuance of common stock in private placement   10,000  
Proceeds from exercise of preferred stock warrants   268  
Proceeds from a research, development and commercialization agreement   1,000  
Net cash (used in) provided by financing activities (4,184) 170,785 14,638
Net (decrease) increase in cash, cash equivalents and restricted cash (120,338) 103,278 10,167
Cash, cash equivalents and restricted cash at beginning of year 125,313 22,035 11,868
Cash, cash equivalents and restricted cash at end of year 4,975 125,313 22,035
Supplemental disclosure of cash flow information      
Cash paid for interest 1,049 1,275 479
Supplemental Disclosures of Non-cash Investing and Financing Information      
Purchase of property and equipment included in accounts payable 270 205 255
Offering costs included in accounts payable     259
Embedded interest associated with program fees $ 3,144    
Vesting of early exercised shares   8 $ 86
Conversion of redeemable convertible preferred stock and warrants into common stock upon IPO, net of issuance costs   187,244  
Reclassification of redeemable convertible preferred stock warrant liability to equity   $ 734